Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Catalyst Pharm Inc (CPRX)

Catalyst Pharm Inc (CPRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 417,702
  • Shares Outstanding, K 103,648
  • Annual Sales, $ 102,310 K
  • Annual Income, $ 31,880 K
  • 60-Month Beta 1.41
  • Price/Sales 3.63
  • Price/Cash Flow 12.86
  • Price/Book 2.83
Trade CPRX with:

Options Overview

Details
  • Implied Volatility 94.63%
  • Historical Volatility 62.11%
  • IV Percentile 9%
  • IV Rank 11.19%
  • IV High 345.59% on 03/16/20
  • IV Low 63.02% on 07/02/20
  • Put/Call Vol Ratio 0.02
  • Today's Volume 487
  • Volume Avg (30-Day) 1,382
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 11,840
  • Open Int (30-Day) 12,808

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate 0.09
  • Number of Estimates 4
  • High Estimate 0.10
  • Low Estimate 0.07
  • Prior Year 0.07
  • Growth Rate Est. (year over year) +28.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.54 +13.84%
on 01/27/21
4.82 -16.39%
on 02/10/21
+0.43 (+11.94%)
since 01/22/21
3-Month
3.30 +22.12%
on 12/31/20
4.82 -16.39%
on 02/10/21
+0.55 (+15.80%)
since 11/24/20
52-Week
2.55 +58.04%
on 03/13/20
5.19 -22.35%
on 07/09/20
-0.88 (-17.92%)
since 02/24/20

Most Recent Stories

More News
Catalyst Pharmaceuticals Announces Support of Rare Disease Day 2021

Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating,...

CPRX : 4.03 (+0.37%)
3 Biotech Stocks on the Robinhood 100 to AVOID

The Robinhood app is popular among millennial investors. And as the Covid-19 pandemic focused attention on the biotech industry last year, many young investors rushed to bet on the sector. Though market...

CPRX : 4.03 (+0.37%)
VXRT : 7.34 (+8.10%)
SRNE : 10.97 (-0.32%)
Catayst (CPRX) Provides Long-Term Portfolio Expansion Plans

Catalyst (CPRX) plans to expand its product portfolio beyond Firdapse.

ALKS : 19.88 (+1.17%)
HALO : 51.45 (+8.98%)
CPRX : 4.03 (+0.37%)
ASLN : 3.52 (+3.23%)
Catalyst Pharmaceuticals Announces Strategic Plan for Product Portfolio Expansion for Long-Term Success and Provides Corporate Update

-- Company to Expand R&D Focus for Pipeline Growth to include Earlier Stage Programs and Validated Technology Platforms

CPRX : 4.03 (+0.37%)
Catalyst Pharmaceuticals (CPRX) Jumps: Stock Rises 5.5%

Catalyst Pharmaceuticals (CPRX) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

CPRX : 4.03 (+0.37%)
BXRX : 1.5000 (+4.17%)
Why Is Catalyst (CPRX) Up 4.4% Since Last Earnings Report?

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

CPRX : 4.03 (+0.37%)
Catalyst's (CPRX) Q3 Earnings Beat Estimates, Revenues Miss

Catalyst (CPRX) beats on earnings but misses sales estimates in the third quarter of 2020.

BLRX : 3.50 (+5.11%)
CNCE : 6.85 (unch)
CPRX : 4.03 (+0.37%)
ATXI : 5.18 (+5.71%)
Catalyst Pharmaceutical (CPRX) Tops Q3 Earnings Estimates

Catalyst (CPRX) delivered earnings and revenue surprises of 22.22% and -6.10%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

CPRX : 4.03 (+0.37%)
Catalyst Pharmaceuticals Announces Third Quarter 2020 Financial Results and Provides Business Update

- Firdapse(R) Third Quarter Net Revenues of $29.2 Million

CPRX : 4.03 (+0.37%)
Catalyst (CPRX) to Report Q3 Earnings: What's in the Cards?

Catalyst (CPRX) will provide updates on earnings and revenues when its releases third-quarter 2020 results.

BLUE : 25.92 (+1.17%)
CPRX : 4.03 (+0.37%)
ASND : 153.84 (+0.62%)
AXLA : 5.84 (-1.35%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), anti-MuSK antibody positive myasthenia gravis...

See More

Key Turning Points

3rd Resistance Point 4.19
2nd Resistance Point 4.14
1st Resistance Point 4.09
Last Price 4.03
1st Support Level 3.99
2nd Support Level 3.94
3rd Support Level 3.89

See More

52-Week High 5.19
Fibonacci 61.8% 4.18
Last Price 4.03
Fibonacci 50% 3.87
Fibonacci 38.2% 3.56
52-Week Low 2.55

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar